![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
We retrospectively analyzed data of 47 patients aged 60 years or older, hospitalized in our institution with the diagnosis of acute myelogenous leukemia (AML), and searched for prognostic factors. Induction with anthracyclines significantly correlated with better complete remission (CR) rate (P =0.0016) and overall survival (OS) (P <0.001). Another factor significantly affecting CR rate was higher age (>70 years) (P =0.042). Therapy-non-related factors predictive for shorter OS in univariate analyses were age older than 70 years (P =0.003), percentage of blasts in bone marrow more than 80% (P =0.048), serum lactate dehydrogenase level higher than 250 U l m 1 (P =0.032). In stepwise cox proportional hazard regression model, all the four factors predictive for poor OS remained to be independently and significantly prognostic for shorter OS. Only two patients receiving anthracyclines died within 30 days and the frequency was not different from that in patients not receiving anthracyclines. The use of anthracyclines as induction therapy is recommended even in the elderly patients.